The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Subscribe To Our Newsletter & Stay Updated
